Introduction
O rgan retrieval associated with organ transplantation is a validated procedure for treating patients with end-stage organ failure. 1 Organ transplantation improves life expectancy and simultaneously reduces the use of medical resources for managing organ failure. 2 In 2014, 118 646 patients around the world, including 40 201 in Europe, received an organ transplant. 3 This therapy avoids the occurrence of repeated hospitalizations and reduces patient morbidity. 4 In the last 10 years, the number of patients awaiting transplants has gradually increased, exceeding 63 000 in the 28 EU Member States. Despite the development of multiple international organ procurement networks and 11 492 European deceased donors, in 2014, the number of available grafts to meet the needs of the European population remained insufficient. 3 That same year, 4100 people across the continent died while waiting for a transplant.
With more than 12 713 patients awaiting transplantation in 2014, France is also engaged in the race for organ procurement. 5 From year to year, needs have progressed with the expansion of medical indications for transplantation and the ageing population. During the last decade, French legislation has evolved to stimulate the development of transplantation. The health ministry developed successive graft plans to meet the graft needs and better adapt to changes in the donor population. 6 The implementation of hospital coordination throughout the country and the allocation of human and financial resources resulted in 1635 brain death donors in 2014 and 5370 transplant recipients. 3 Transplantation is a very expensive treatment, but in kidney transplantation, for example, treating chronic terminal kidney failure with a graft is less costly for the community than dialysis treatment. In 2007, the cost of dialysis was assessed at approximately E89 000 per year, whereas the cost of transplantation is only approximately E20 000 per year per person for the lifetime of the graft. 7 Moreover, transplantation significantly improves a patient's duration and quality of life. 7 Ultimately, transplantation is the most cost-effective supportive treatment, providing the best quality of life for patients with chronic end-stage renal disease. Although organ recovery activities effectively addresses vital needs, in the context of health budgets, a monetary assessment is required for organ recovery to be efficiently and sustainably integrated into national health policies. An analysis of recent cost data would also inform financial management by hospitals and would provide researchers and health economists with real-world data for future economic evaluations. Despite the importance of these data, available medico-economic studies on organ recovery activities in France and Europe are either scarce or outdated. 8, 9 Other studies have used old data or have calculated the cost of organ acquisition but not organ recovery. 10, 11 In the Australian public health system, the costs of kidney and liver acquisition were assessed in 1996 and were found to be $1860 and $5049, respectively. 10 A publication has found that pancreas procurement in the French system costs E1086. 8 A possible explanation for the lack of data may be the difficulty in assessing the cost of an activity carried out during a multi-step emergency procedure, which compromises the real-time acquisition of cost data.
The development of hospital discharge databases in each French hospital and the implementation since 2006 of a national cost study provide an opportunity to solve this problem. Medico-economic and medico-administrative databases could be used to assess organ recovery costs, as has been done for other procedures. 12 Moreover, these databases may allow us to observe changes in donor populations, which is relevant for adjusting future graft plans to enhance organ recovery activity.
The main objective of this study was to assess organ recovery costs from 2007 to 2014 in the French healthcare system based on the national hospital discharge database and a national cost study. The secondary objective was to describe the variability in the population of deceased organ donors during this same period.
Methods

Study design
This study was based on discharge data for public and private French hospitals performing organ recovery from January 2007 to December 2014. Direct medical costs were estimated from the hospital's perspective. Direct non-medical costs and indirect costs were not considered in this study. The timeframe considered was from the beginning of the hospital stay during which organ recovery was performed until the end of the hospital stay. Costs related to liquid preservation, family management, machine perfusion and organ shipment were not included.
Databases
The national hospital discharge database and the French national cost study were used for this analysis. 13, 14 Their use as a medicoadministrative database and an economic database, respectively, has allowed researchers to conduct previous medico-economic analyses. 15 For each deceased donor identified during the eight consecutive years, a discharge abstract combining personnel and stay data was extracted from the national hospital discharge database.
All resources consumed during hospital stays for organ recovery were identified and quantified using the discharge abstract and were valued using the national cost study. The national cost study is annually updated with cost accounting data from representative hospitals. 16 Patients and organ collection All brain death donors who underwent kidney, liver, pancreas, intestine, heart, lung or heart-lung block recovery in one of the 181 public or private French hospitals between 2007 and 2014 were eligible. Kidney recovery in this paper systematically refers to the removal of both kidneys. Donors were excluded if hospital stay data were not correctly provided and/or if cost data were unavailable. To enhance representativeness, the French national cost study does not assess the costs of diagnosis in related groups with sparse numbers of patients providing data. Donors were identified in a medical database and selected using the Common Classification of Medical Procedures codes corresponding to organ recovery from donors after brain death (Supplementary Appendix S1). Living donors and donors after circulatory death were excluded.
Identification and quantification of cost components
Because cost information in the French healthcare system was not available at the individual level, the resources consumed during the organ recovery stay and organ recovery procedure were identified, quantified and valued retrospectively at the diagnosis-related group (DRG) level from the national cost study. Eight items were identified (Supplementary Appendix S2). Surgery, anaesthesia, reanimation, intensive care, ongoing monitoring, biology and imaging were sub-divided into five sub-items: medical staff, non-medical staff, nursing staff, maintenance, depreciation and cost of structure occupation. Medical logistics items were regrouped into sterilization, biomedical engineering, hygiene, vigilance and pharmacy groups.
Valuation of cost components
All cost components were valued in 2014 Euros. Items identified and quantified were valued using the corresponding annual national cost study. As organ recovery is not a classifying procedure, hospital stays for organ recovery may correspond to either a medical DRG or a surgical DRG, according to the main reason for hospital admission. The valuation process requires a specific methodology for each case.
For a surgical DRG, each surgical act related to (or not) an organ recovery procedure is characterized by the relative cost indexes (RCIs). An RCI is used to assess the cost of a procedure carried out in ideal conditions. 17 These indexes are commonly used to break down the overall cost of surgery activities according to the number of RCIs specific to each procedure. 18 For each donor, we assessed a ratio corresponding to the portion of RCIs related to organ recovery out of the total number of RCIs related to surgical activities. Thus, surgery, anaesthesia, biology, imaging and medical logistics were valued from national cost data weighted by the ratio determined to relate exclusively to organ recovery. Regarding reanimation, intensive care and ongoing monitoring, discussions with hospital co-ordinators of organ procurement allowed us to elaborate the working hypothesis that expenditures related to organ recovery are exclusively focused on the last day of the stay. For each donor, we added the costs of re-animation, intensive care and ongoing monitoring and divided this sum by the corresponding length of stay.
For a medical DRG, the valuation of surgery and anaesthesia items with national cost study data entails the risk of greatly underestimating these items. Thus, surgical and anaesthesia items resulting from a medical DRG were valued using mean costs of surgery and anaesthesia during a surgical DRG. This approach was tested using a sensitivity analysis. All other items, including reanimation, intensive care, ongoing monitoring, biology, imaging and medical logistics, were valued using national economic data weighted by the length of stay corresponding to each donor.
Outcomes
Organ recovery cost assessment from 2007 to 2014
Five cost evaluations were conducted. Each explored a specific characteristic of organ recovery procedures. All costs are presented according to their mean, minimum, maximum and standard deviation (SD).
(1) The cost of hospital stays during which an organ recovery procedure was performed to obtain an overview of hospital costs related to organ recovery activity. (2) The cost of hospital stays corresponding to the French classification for organ recovery procedures based on OP (organ procurement) classes:
OP1: Kidneys and/or liver. OP2: Kidneys, liver, heart, pancreas, lung(s) and/or the intestine or at least seven organs. OP3: Other organ recovery.
(3) The cost of organ recovery procedures, according to OP classification, to assess the portion of hospital stay costs related exclusively to organ recovery activities. (4) The cost of separate kidney, liver, pancreas, intestine, heart, lung or heart-lung block recovery regardless of the organs recovered to obtain the cost for each organ recovered to inform future medico-economic studies. (5) The cost of all organ recovery combinations to better reflect the realities of organ recovery.
Sensitivity analysis
For objective 3, a sensitivity analysis was conducted to test the choice to value surgical and anaesthesia items during a medical DRG using the mean costs of surgery and anaesthesia during a surgical DRG.
The results of the sensitivity analysis are presented using the real surgical and anaesthesia item costs from a medical DRG.
Changing population of deceased organ donors between 2007-2014
General trends regarding organ recovery activity in France were assessed according to several parameters from 2007 to 2014:
Number of deceased organ donors, age and sex of donors. Number of organ recovery procedures, including one, two, three or more organs recovered and the mean number of organs recovered by the procedure. Number of organ recovery procedures based on OP class (OP1, OP2 or OP3). Number of most common combinations of organ recovery procedures.
Results
From 2007 to 2014, a total of 12 629 brain death donors were included in the analysis, corresponding to a total of 11 920 pairs of kidneys, 8788 livers, 1450 pancreases, 1796 lungs, 3971 hearts, 324 heart-lung blocks and 233 intestines.
Organ recovery cost assessment from 2007 to 2014
The mean cost of hospital stays during which an organ recovery procedure was performed was assessed at E7469 (SD = E10 894) but differed strongly between medical DRGs E4153 (SD = E4264) and surgical DRGs E18 202 (SD = E17 126) (table 1) . According to the French OP classification, the costs of hospital stays during which an organ recovery corresponding to an OP1, OP2 or OP3 procedure was performed were assessed at E6483 (SD = E9045), E6033 (SD = E6669) and E9044 (SD = E13 239), respectively (table 1) .
According to the French OP classification, the costs of OP1, OP2 and OP3 procedures were assessed at E1881 (SD = E1577), E2, 188 (SD = E1835) and E2368 (SD = E2343), respectively (table 1) . These results were influenced by our methodological choices. Using the real surgical and anaesthesia costs of a medical DRG changed the cost assessments; OP1, OP2 and OP3 procedures were assessed at E1133 (SD = E1783), E1570 (SD = E2078) and E1750 (SD = E2583), respectively (table 1).
The mean costs of separate kidney, liver, pancreas, intestine, heart, lung and heart-lung block recovery, regardless of the organs recovered, were assessed at E1432 (SD = E1342), E502 (SD = E782), E354 (SD = E475), E362 (SD = E1559), E542 (SD = E955), E977 (SD = E1196) and E737 (SD = E637), respectively (table 1) .
The costs of all organ recovery combinations identified are presented in table 2 and arranged from the most frequent to the least frequent procedure.
Changing population of deceased organ donors between 2007 and 2014
In France, the number of organ donors slightly increased from 1575 in 2007-1612 in 2014. Although donors were predominantly men, the gap between male and female donors tended to narrow over time. During this period, the mean age of donors gradually increased from 50 to 57 years. Female donors were generally older than male donors, and this difference slightly increased over the course of this study (table 3) . Although the number of donors increased only marginally between 2007 and 2014, the number of organs recovered increased more dramatically. In fact, the number of organs recovered from donors gradually increased from 2.22 in 2007-2.32 in 2014. The number of organ recovery procedures with only one organ recovered progressively decreased, while the number of organ recovery procedures with 2, 4 or 5 organs recovered simultaneously increased (table 3) .
Discussion
The use of the national hospital discharge database and the national cost study made it possible to assess, for the first time on a large scale, the different costs pertaining to organ recovery activities and to follow the evolution of these practices over eight consecutive years in the French healthcare system. The primary achievement of this study is the exploitation of data from 12 629 donors and 28 482 recovered organs, providing considerable validity to the results. The mean cost of a hospital stay during which an organ recovery procedure was performed was assessed at E7469 (SD = E10 894) but differed greatly for medical DRGs E4153 (SD = E4264) and surgical DRGs E18 202 (SD = E17 126). Brain death donors were distributed into more than 430 DRGs reflecting the diversity of analyzed cases and explaining the large standard deviations in assessed costs. The implementation of a specific methodology considering the strengths and weaknesses of the exploited databases allowed us to present different components of the costs associated with organ recovery activities. These costs might be used as unit costs in economic evaluations performed in the French context and as a reference for international cost comparisons. Our results will allow hospital managers performing organ recovery to compare their own cost accounting data to national average costs and to compare their practices to national trends for better resource management. Moreover, organ recovery activities are currently paid by fee-for-service. 19 This requires payers to reimburse the healthcare provider for each service performed without incentive to implement cost-saving measures. As national benchmark metrics, these cost and practice data could be used by policy makers for building new payment models based on performance and efficiency.
The majority of economic publications addressing issues related to organ grafts have focused on the cost of organ transplantation. In a major publication including 1333 patients who underwent solid organ transplantation between 1995 and 2003 in Canada, Levy et al. were unable to estimate costs prior to transplantation because economic data on costs associated with organ donation were not available. 20 The cost of kidney and pancreas procurement in the Italian healthcare system was assessed at $1400, which is close to our estimate. 9 In Spain, a cost-benefit estimation found that kidney procurement cost $3162. 21 This estimate is higher than our estimate of E1432 for kidney recovery, but the difference can be explained by the inclusion of the cost of preservation fluid.
In the USA, as in France, the government must find solutions to address the increasing costs of organ procurement and organ shortages. A recent US study compared costs between organ recoveries performed in hospitals and those performed in an organ procurement organization (OPO) facility. 22 The mean cost of recovery per donor was assessed at $33 164 (SD: $13 578) in American hospitals vs. $16 153 (SD: $5698) in the OPO, with the authors concluding that organ recovery performed at an OPO facility is an effective way to minimize organ recovery costs. However, we should be cautious in comparing France with the US. The US costs are higher mainly because of a price effect. Moreover, the difference may also be explained by the integration in the American study of building construction costs, which alone represent two-thirds of the total cost. Furthermore, the organ yield was assessed as 2.7 organs per donor recovered in US hospitals vs. 3.4 organs per donor in OPO facilities. In French hospitals, the organ yield was assessed as 2.3 per donor. As in the US, the externalization of organ recovery activities through the development of OPO facilities in France could not only reduce costs but also increase the number of available organs.
The main limitation of our work concerns the costing method used. Bottom-up microcosting is considered the best method to estimate hospital service costs. 23 However, as individual costs were not available, organ recovery stays were valued at the DRG level from the national average cost database. Moreover, surgery and anaesthesia were assessed using the RCI, although the RCI does not reflect the actual time spent by surgeons and anaesthesiologists. 17 Mercier et al. suggested the introduction of a time-driven activitybased costing method to provide more accurate weighting with minimal adjustment. 24 However, this weighting method seems to be more appropriate for single institutions rather than a national database. The first costing method used to assess the cost of organ recovery procedures is preferred over the second method because surgical DRG data more accurately reflect the cost of surgery and anaesthesia for a surgical procedure. Effectively, the sensitivity analysis highlights the underestimation of the organ recovery costs when they were valued by real medical DRG data.
Extrapolation of our method to other countries requires the availability of both a national hospital discharge database and a national cost study. A majority of developed countries have both databases, making it possible to conduct similar analyses to better understand organ recovery activities and to enable future comparisons. For years, France has ranked among the top 10 countries for organ recovery worldwide, which gives more weight and representativeness to results arising from the exploitation of the French databases.
The globalization of organ shortage issues and global trends regarding the control of healthcare budgets force states to optimise available resources, which involves analysis of the costs incurred, the results obtained and constant innovation of strategies for responding to this vital problem. 25 Although costs are the main challenge for the successful functioning of organ recovery activities, other aspects such as organization modalities should be considered to increase the availability of organs. 26 
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Key points
The use of national databases made it possible to assess organ recovery costs on a nationwide scale and to follow the evolution of practices over a long period. The mean cost of hospital stays during which an organ recovery procedure was performed was assessed at E7469 (SD = E10 894) but differed greatly for medical DRGs at E4153 (SD = E4264) and surgical DRGs at E18 202 (SD = E17 126). Although the number of donors increased only marginally, the number of organs recovered increased more dramatically due to changes in practices. Extrapolation of the methodology to other countries requires the availability of both a national hospital discharge database and a national cost study. Cost management is the main challenge for the successful functioning of organ recovery activities, but other aspects such as organization modalities should be considered to increase organ availability.
